E0 ConsensusModerate confidencePEM not requiredReview-NarrativePeer-reviewedMachine draft
Standard · 3 min
Autoimmune Autonomic Neuropathy: From Pathogenesis to Diagnosis.
Nakane, Shunya, Koike, Haruki, Hayashi, Tomohiro et al. · International journal of molecular sciences · 2024 · DOI
Quick Summary
This review describes autoimmune autonomic ganglionopathy (AAG), a rare condition where the immune system attacks nerve cells that control automatic body functions like heart rate and blood pressure. The authors explain how doctors can diagnose AAG and how it differs from other similar conditions, including ME/CFS and long COVID, which can have overlapping symptoms.
Why It Matters
This review is important for ME/CFS patients and researchers because ME/CFS shares overlapping symptoms with AAG and other autoimmune neuropathies, yet may have distinct underlying mechanisms. Clarifying the diagnostic criteria and clinical features that distinguish AAG from ME/CFS can help ensure accurate diagnosis and appropriate treatment, preventing misclassification and enabling better clinical management.
Observed Findings
AAG presents with variable disease onset (acute or chronic) and heterogeneous clinical courses
Ganglionic acetylcholine receptor (gAChR) autoantibodies are a key diagnostic marker for AAG
AAG shares overlapping autonomic symptoms with POTS, ME/CFS, and long COVID, making differential diagnosis clinically challenging
Imune-mediated neuropathies and non-neuropathic conditions can present with similar autonomic dysfunction features
Careful history-taking regarding mode of onset and disease progression is essential for accurate diagnosis
Inferred Conclusions
Accurate AAG diagnosis requires integration of clinical history, disease progression patterns, and autoantibody detection rather than reliance on any single parameter
Other conditions presenting with autonomic dysfunction—including ME/CFS, POTS, and long COVID—must be actively differentiated from AAG through systematic clinical and laboratory evaluation
Clinicians should maintain high diagnostic suspicion for AAG while recognizing its overlapping presentation with multiple other disease entities
Remaining Questions
What are the precise prevalence rates of gAChR autoantibodies in ME/CFS, POTS, and long COVID patient populations?
What This Study Does Not Prove
This review does not establish that ME/CFS is caused by autoimmune mechanisms or gAChR autoantibodies, nor does it prove that patients with ME/CFS have AAG. The overlap in symptoms does not imply shared etiology; the authors note that differential diagnosis can be challenging but does not provide evidence that ME/CFS patients commonly have undiagnosed AAG.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →